HR 1672In committeeHealthhouse

Maintaining Investments in New Innovation Act

Introduced Feb 27, 2025 by Rep. Donald G. Davis

IntroducedCommitteeFloorCongressLaw

It's waiting on a committee vote to reach the full chamber. Most bills never leave this stage.

Latest action · Feb 27, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Read it on Congress.gov

What it does

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Summary by the Congressional Research Service.

Roll-call votes

No floor votes yet — it hasn't reached the floor of either chamber.